The official advocacy organization for pharmacist women in the United States
Pharmacist Moms Group™
45,000+ Members
Over 6 Million posts, comments and reactions in 2020
60,000+ Followers on social media platforms
The Largest Community of Women Pharmacists in the US
Founded in 2017, Pharmacists Moms Group was created to provide women pharmacists the opportunity to network, collaborate and offer genuine feedback in a closed-door, trusted setting. The organization has quickly grown to over 45,000 members and 60,000 followers on our social media platforms.
While we may not be able to control what happens to us, we can ALWAYS control how we respond. Working on self-awareness and self-improvement will certainly create positive habits to help you when you are stuck.
Read on to learn more about Jennifer’s path to pharmacy ownership, and to learn how COVID-19 and the Oregon wildfires have impacted her business.
Miss America 2020, Camille Schrier, has been a proud, self-described “science nerd” for as long as she can remember. We caught up with Camille to get a student’s perspective on the future of the profession.
A ketogenic diet and its key metabolite, β-hydroxybutyrate, enhance the efficacy of CAR T-cell therapy by improving metabolic fitness, cytokine production, and cellular expansion, offering a promising, safe strategy for optimizing cancer immunotherapy.
Glucagon-like peptide 1 (GLP1) receptor agonists were shown to be associated with a reduced risk of venous thromboembolism (VTE), while high dietary fiber intake was shown to enhance microbiome health, lower graft-versus-host disease (GVHD) severity, and improve overall survival following allogeneic hematopoietic cell transplantation.
In newly diagnosed average and high standard risk B-cell acute lymphoblastic leukemia (B-ALL), blinatumomab improved disease-free survival (DFS) by approximately 97.5% and 94.1%, respectively.
Donald Moore discusses some of the obstacles that bispecific antibodies have faced in community cancer centers, including misconceptions coupled with a prevalent toxicity profile.
Jose Tinajero discusses how certain mutations can be indicators of blinatumomab treatment failure in patients with B-cell acute lymphoblastic leukemia.
Mazyar Shadman, MD, MPH, discusses the continued efficacy of zanubrutinib in patients with chronic lymphocytic leukemia.